Kisspeptin peptide
Kisspeptin-54
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Kisspeptin-54 →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
- Emerging
Alpha-MSH-derived tripeptide
KPV
KPV is the C-terminal tripeptide Lys-Pro-Val of alpha-melanocyte-stimulating hormone. Preclinical studies associate KPV and related analogs with anti-inflammatory and antimicrobial effects, including modulation of NF-kB-linked signaling and epithelial inflammatory responses.
Evidence and record details
Evidence integrity map
Human 0Preclinical 19Durable IDs 30Open signals 3- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- 24 open research questions
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Endogenous dipeptide
Kyotorphin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Kyotorphin →Antimicrobial peptide fragment
Lactoferricin B
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Lactoferricin B →- Developing
Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Research reference
Leech-derived tryptase inhibitor
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Leech-derived tryptase inhibitor →Endogenous opioid peptide
Leu-enkephalin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Leu-enkephalin →- Developing
Leuprolide is a synthetic nonapeptide agonist of the gonadotropin-releasing hormone receptor. Initial continuous exposure can transiently increase luteinizing hormone, follicle-stimulating hormone, and gonadal steroid concentrations; sustained depot exposure then desensitizes pituitary GnRH signaling and suppresses gonadal steroid production. This biphasic action supports product-specific uses in prostate cancer, central precocious puberty, endometriosis, and uterine fibroids, while stimulation-test and assisted-reproduction contexts use different timing and objectives.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
GnRH analog salt/reference
Leuprolide acetate
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Leuprolide acetate →- Emerging
Linaclotide is a guanylate cyclase-C agonist peptide studied for gastrointestinal symptoms. Constipation-related conditions, age groups, and bowel-preparation studies are distinct settings and should be interpreted separately.
Evidence and record details
Evidence integrity map
Human 0Preclinical 1Durable IDs 5Open signals 1- Publication state
- Published profile
- Verified source records
- 167 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Peptide metabolite
Linaclotide active metabolite MM-419447
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Linaclotide active metabolite MM-419447 →- Emerging
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist investigated in type 2 diabetes and weight management. WPF separates findings by dose, population, indication, comparator, and endpoint so that one result is not generalized to every setting.
Evidence and record details
Evidence integrity map
Human 0Preclinical 2Durable IDs 6Open signals 1- Publication state
- Published profile
- Verified source records
- Evidence record in preparation
- Chemistry record
- No governed record published
- Regulatory entries
- No published regulatory entry on file
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Synthetic peptide
Livagen
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Livagen →- Emerging
Human cathelicidin antimicrobial peptide with membrane-active, immunomodulatory, and wound-biology roles.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Vasopressin-related peptide
Lypressin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Lypressin →Antimicrobial peptide
Magainin 1
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Magainin 1 →Antimicrobial peptide
Magainin 2
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Magainin 2 →Proglucagon-derived peptide
Major proglucagon fragment
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Major proglucagon fragment →
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.